Trading Halt
Filed with ASX · · 2 pages · English
On 6ix: 6ix.com/news/trading-halt-697
Trading in the securities of Cleo Diagnostics Ltd (‘COV’) will be halted at the request of COV, pending the release of an announcement by COV. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: x the commencement of normal trading on Friday, 19 December 2025; or x the release of the announcement to the market. COV’s request for a trading halt is attached
Earlier from CLEO Diagnostics
- Cleo Strengthens Cash Position with $1.7m R&D Tax Refund
- CLEO Appoints First Key Opinion Leader to Support US Market
- CLEO Significantly Expands Addressable Market
- CLEO Successfully Completes Stage 1 MDSAP Audit
- Cleo Receives Positive FDA Feedback
Later from CLEO Diagnostics
- CLEO Raises $5m to Support U.S. Market Launch
- Quarterly activities and cashflow report
- CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
- Appendix 4D and Half Yearly Accounts
- CLEO Optimises Biomarker Panel Ahead of FDA Submission
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics